IL112167A - Evaluation of compound activity in the nervous system - Google Patents

Evaluation of compound activity in the nervous system

Info

Publication number
IL112167A
IL112167A IL11216791A IL11216791A IL112167A IL 112167 A IL112167 A IL 112167A IL 11216791 A IL11216791 A IL 11216791A IL 11216791 A IL11216791 A IL 11216791A IL 112167 A IL112167 A IL 112167A
Authority
IL
Israel
Prior art keywords
animals
lesions
active compounds
vincristine
compound
Prior art date
Application number
IL11216791A
Other languages
English (en)
Hebrew (he)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of IL112167A publication Critical patent/IL112167A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL11216791A 1990-05-22 1991-05-17 Evaluation of compound activity in the nervous system IL112167A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9006399A FR2662355B1 (fr) 1990-05-22 1990-05-22 Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
IL9817591A IL98175A (en) 1990-05-22 1991-05-17 1-) 2-Naphthylethyl (-4-) 3-trifluoromethylphenyl (-1, 2, 3, 6-tetrahydropyridine for the treatment of brain and nerve diseases

Publications (1)

Publication Number Publication Date
IL112167A true IL112167A (en) 1996-01-31

Family

ID=9396855

Family Applications (3)

Application Number Title Priority Date Filing Date
IL11216791A IL112167A (en) 1990-05-22 1991-05-17 Evaluation of compound activity in the nervous system
IL9817591A IL98175A (en) 1990-05-22 1991-05-17 1-) 2-Naphthylethyl (-4-) 3-trifluoromethylphenyl (-1, 2, 3, 6-tetrahydropyridine for the treatment of brain and nerve diseases
IL11216794A IL112167A0 (en) 1990-05-22 1994-12-27 Evaluation of neuronally active compounds

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL9817591A IL98175A (en) 1990-05-22 1991-05-17 1-) 2-Naphthylethyl (-4-) 3-trifluoromethylphenyl (-1, 2, 3, 6-tetrahydropyridine for the treatment of brain and nerve diseases
IL11216794A IL112167A0 (en) 1990-05-22 1994-12-27 Evaluation of neuronally active compounds

Country Status (17)

Country Link
US (3) US5229389A (da)
EP (2) EP0655247B1 (da)
JP (2) JP2618115B2 (da)
KR (1) KR0181330B1 (da)
AT (2) ATE207747T1 (da)
BR (1) BR9105015A (da)
CA (2) CA2365832C (da)
CY (1) CY2283B1 (da)
DE (2) DE69132797T2 (da)
DK (2) DK0458696T3 (da)
FR (1) FR2662355B1 (da)
HK (1) HK1001471A1 (da)
HU (1) HU208922B (da)
IE (1) IE911707A1 (da)
IL (3) IL112167A (da)
TW (1) TW216771B (da)
ZA (1) ZA913865B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0192386A (ja) * 1987-10-05 1989-04-11 Hitachi Ltd 密閉循環型吸収式冷凍機及び吸収式冷凍機用吸収液
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5618822A (en) * 1990-05-23 1997-04-08 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
US5557209A (en) * 1990-12-20 1996-09-17 Hewlett-Packard Company Identification of pin-open faults by capacitive coupling through the integrated circuit package
FR2690158B1 (fr) * 1992-04-17 1994-07-22 Sanofi Elf Nouveau derive arylpiperidinique, procede pour sa preparation et compositions pharmaceutiques le contenant.
FR2702656B1 (fr) * 1993-03-18 1995-06-16 Sanofi Elf Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs.
US5698565A (en) * 1995-06-09 1997-12-16 Hoffmann-La Roche Inc. Use of phenoxy-pyridine derivatives
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
JP3468526B2 (ja) * 1995-10-26 2003-11-17 サノフィーサンテラボ 筋萎縮性側索硬化症治療薬調製のための１−（２−ナフタ−２−イルエチル）−４−（３−トリフルオロメチルフェニル）−１，２，３，６−テトラヒドロピリジンの使用
FR2740343B1 (fr) * 1995-10-26 1999-01-22 Sanofi Sa Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
DE69736976T2 (de) * 1996-03-29 2007-10-18 Trustees Of Boston University, Boston Mit Alzheimer Krankheit verknüpften Verfahren zur Diagnose, zur Herstellung von Medikamenten und zum Screenen von Substanzen sowie aus Beta-Amyloid abgeleiteten Peptiden
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
FR2757161B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa Diphenylalkyl-tetrahydropyridines
FR2757510B1 (fr) * 1996-12-23 2000-01-07 Sanofi Sa Forme microparticulaire d'un derive de tetrahydropyridine
FR2757512B1 (fr) * 1996-12-24 1999-03-12 Sanofi Sa Utilisation de benzoylalkyl-1-1,2,3,6-tetrahydropyridines
EP0954311A1 (fr) * 1997-02-03 1999-11-10 Sanofi-Synthelabo Utilisation du 1- 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane pour la preparation de medicaments destines aux traitements de troubles cerebraux et neuronaux
FR2762514B1 (fr) 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
FR2763847B1 (fr) * 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
CO4980891A1 (es) * 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
FR2771007B1 (fr) * 1997-11-14 2000-12-01 Sanofi Sa Association de principes actifs pour le traitement de la demence senile du type alzheimer
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
TWI237035B (en) * 1998-07-24 2005-08-01 Polyplastics Co Polyacetal copolymer
KR101130212B1 (ko) * 2002-03-27 2012-04-13 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 사용법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2639226B1 (fr) * 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Also Published As

Publication number Publication date
CY2283B1 (en) 2003-07-04
ATE132369T1 (de) 1996-01-15
EP0458696A2 (fr) 1991-11-27
FR2662355B1 (fr) 1994-11-10
IE911707A1 (en) 1991-12-04
FR2662355A1 (fr) 1991-11-29
EP0655247B1 (fr) 2001-10-31
HU911729D0 (en) 1991-12-30
BR9105015A (pt) 1993-05-25
EP0655247A1 (fr) 1995-05-31
KR0181330B1 (ko) 1999-03-20
JPH09132535A (ja) 1997-05-20
IL112167A0 (en) 1995-03-15
DK0655247T3 (da) 2002-02-18
CA2042974C (en) 2002-09-17
KR910019617A (ko) 1991-12-19
DK0458696T3 (da) 1996-05-20
US5270320A (en) 1993-12-14
JP2954029B2 (ja) 1999-09-27
JP2618115B2 (ja) 1997-06-11
EP0458696A3 (en) 1992-03-18
DE69132797D1 (de) 2001-12-06
HUT59824A (en) 1992-07-28
CA2365832C (en) 2007-08-07
JPH04226917A (ja) 1992-08-17
ZA913865B (en) 1992-02-26
DE69132797T2 (de) 2002-05-29
IL98175A (en) 1996-01-19
AU7713391A (en) 1991-11-28
ATE207747T1 (de) 2001-11-15
CA2042974A1 (en) 1991-11-22
US5229389A (en) 1993-07-20
HK1001471A1 (en) 1998-06-19
TW216771B (da) 1993-12-01
AU636488B2 (en) 1993-04-29
IL98175A0 (en) 1992-06-21
DE69115989T2 (de) 1996-08-22
US5468753A (en) 1995-11-21
CA2365832A1 (en) 1991-11-23
IE20011078A1 (en) 2002-03-20
HU208922B (en) 1994-02-28
EP0458696B1 (fr) 1996-01-03
DE69115989D1 (de) 1996-02-15

Similar Documents

Publication Publication Date Title
IL112167A (en) Evaluation of compound activity in the nervous system
Murray et al. Learning and memory deficits after lesions of the nucleus basalis magnocellularis: reversal by physostigmine
Fine et al. Transplantation of embryonic ventral forebrain neurons to the neocortex of rats with lesions of nucleus basalis magnocellularis—I. Biochemical and anatomical observations
Will et al. Behavioural and neurochemical effects of chronic intraventricular injections of nerve growth factor in adult rats with fimbria lesions
Savas et al. Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA
Grodsky et al. Insulin and the pancreas
Dixon et al. Reduced evoked release of acetylcholine in the rodent neocortex following traumatic brain injury
Alderson et al. Intravenous self‐administration of nicotine is altered by lesions of the posterior, but not anterior, pedunculopontine tegmental nucleus
TW201726161A (zh) 溶酶體酵素之腦脊髓膜內遞送及其醫療用途
Taslim et al. Role of mouse cerebellar nicotinic acetylcholine receptor (nAChR) α4β2-and α7 subtypes in the behavioral cross-tolerance between nicotine and ethanol-induced ataxia
Pike et al. Post-injury administration of BIBN 99, a selective muscarinic M2 receptor antagonist, improves cognitive performance following traumatic brain injury in rats
Droz et al. Localization of protein metabolism in neurons
Shashoua Molecular and cell biological aspects of learning: toward a theory of memory
Janušonis et al. Diurnal variation of c‐Fos expression in subdivisions of the dorsal raphe nucleus of the Mongolian gerbil (Meriones unguiculatus)
Charlton et al. Substantia nigra degeneration and tyrosine hydroxylase depletion caused by excess S-adenosylmethionine in the rat brain: support for an excess methylation hypothesis for parkinsonism
Cozzi et al. The NADPH-diaphorase-containing system in the brain of the budgerigar (Melopsittacus undulatus)
Shukitt-Hale et al. Nimodipine prevents the in vivo decrease in hippocampal extracellular acetylcholine produced by hypobaric hypoxia
MacKenzie et al. The blood-nerve barrier: an in vivo lanthanum tracer study.
Calzada et al. Effect of steroid hormones and capacitation on membrane potential of human spermatozoa
Lorens et al. Septal choline acetyltransferase immunoreactive neurons: dose-dependent effects of AF64A
Anghileri In vivo distribution of radioactive chromic phosphate: Influence of the particle size and route of injection
Lindner et al. Intraventricular encapsulated calf adrenal chromaffin cells: viable for at least 500 days in vivo without detectable adverse effects on behavioral/cognitive function or host immune sensitization in rats
Jaatinen et al. Ethanol-induced vacuolation in rat peripheral nervous system
Colombo et al. Prolactin and LH release induced by kainic acid administration within the preoptic-suprachiasmatic region in behaving male rats
Lazaris et al. Baseline and 8-OH-DPAT-induced release of acetylcholine in the hippocampus of aged rats with different levels of cognitive dysfunction

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
HC Change of name of proprietor(s)
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees